About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Nevirapine: Not Chiral. Paper: Not Right. Editorial Staff: Not Doing Their Job | Main | Acronym-Fest: GSK and Its DPUs »

December 1, 2011

Worst Biotech CEO of 2011?

Email This Entry

Posted by Derek

I would be neglecting my duties if I didn't mention Adam Feuerstein's "Worst Biotech CEO of 2011" voting, which is going on here. If you have a strong opinion on this matter - and opinions on such things tend to be strong - then hop over and make yours known.

Comments (12) + TrackBacks (0) | Category: Business and Markets


1. johnnyboy on December 1, 2011 10:39 AM writes...

Get in there and vote for the Makena guy - he's the most deserving of the bunch.

Permalink to Comment

2. Nick on December 1, 2011 1:26 PM writes...

I think in the end we'll find biotech/pharmas woes are tied to the same psychopaths who have taken over the financial system.

In many ways the financial systems problems have directly impacted biotech since the markets no longer function as a vehicle to efficiently allocate capital, but rather act in the short term interest of the deviant CEOS.

There are no good guys anymore, just cabals of manipulators and criminals.

Permalink to Comment

3. NH_chem on December 1, 2011 2:17 PM writes...

Does AMRI count? I guess they are not a Biotech but their CEO has certainly screwed things up since deciding that General Electric people know how to set the direction for the company. They have lost many good people over the past 3 years and are a shell of themselves today.

Permalink to Comment

4. tedthechemist on December 1, 2011 4:52 PM writes...

My vote goes to David Brennan - not sure if AZ is a 'biotech' - they claim to be...but as a company-destroying incompetent tosser, he cannot be beaten

Permalink to Comment

5. Anonymous on December 1, 2011 8:58 PM writes...

@ 3 You mean General Eclectic???

Permalink to Comment

6. Anonymous on December 1, 2011 9:09 PM writes...

I voted the Gilead guy 50 times. Such a stupid deal or guy! I was wondering if he would have done it if the money were his.

Permalink to Comment

7. Anonymous on December 1, 2011 9:15 PM writes...

Sudhir Agrawal of Idera. The guy is making oligonucleotide based drugs. He either does know what he is doing or pretends not to know that oligonucleotides cannot get into cells except hepatocytes.

Permalink to Comment

8. Not an Amgenite anymore! on December 1, 2011 9:53 PM writes...

Why in the world is Kevin Sharer not on this list?

Permalink to Comment

9. Anonymous on December 2, 2011 2:09 AM writes...

Why not run a blog on the "BEST" CEO of 2011? There's so much crap out there. Let's focus on the positive and the "movers, shakers and bakers". HHAAAA should be interesting!!!!

Permalink to Comment

10. bbooooooya on December 2, 2011 8:23 AM writes...

"Why not run a blog on the "BEST" CEO of 2011?"

I think Feuerstein also does one of these each year.

Clear front runners this year have to be Schaeffer Price from VRUS (who got that ridiculous price from GILD, well done for this shareholders) and David Hung from Medivation.

Permalink to Comment

11. BioBearHedge on December 2, 2011 12:30 PM writes...

Incompetent management is not all that bad. You can make a lot of money short-selling and or put options of these borderline fraudulent companies. In addition, the SEC tends to look the other way when you make big profits from short-selling by placing a bet on negative inside information. Be on the lookout for forced IPO’s of biotechs in the near future that will be ripe for a bombing from a naked short-sell block trade.

Permalink to Comment

12. cliffintokyo on December 5, 2011 3:54 AM writes...

@9: Not sure whether you are serious, but the scientist-execs (if there are any left) would be at the top of my list - need to investigate.....

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry